{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine&page=2", "query": { "intervention": "Diphenhydramine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 488, "total_pages": 49, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Diphenhydramine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T21:31:38.420Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02709018", "title": "A Controlled Trial of Losartan in Posttraumatic Stress Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "losartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 149, "start_date": "2016-07-16", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2021-03-12", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 6, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Bethesda, Maryland + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Belmont", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709018" }, { "nct_id": "NCT06801626", "title": "Novel Strategies for Reducing Burn Scar Itch", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Burn Scar", "Itch Scarring", "Wound" ], "interventions": [ { "name": "Famotidine and 4% topical cromolyn sodium", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "The University of Texas Medical Branch, Galveston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 44, "start_date": "2025-03-01", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 1, "location_summary": "Galveston, Texas", "locations": [ { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06801626" }, { "nct_id": "NCT00095550", "title": "Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Irbesartan/HCTZ", "type": "DRUG" }, { "name": "Irbesartan monotherapy", "type": "DRUG" }, { "name": "HCTZ monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 496, "start_date": "2004-10", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2011-04-15", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 84 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Columbiana", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095550" }, { "nct_id": "NCT01411410", "title": "Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Copanlisib (BAY80-6946)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2011-08-24", "completion_date": "2015-06-29", "has_results": false, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 3, "location_summary": "St Louis, Missouri • New York, New York • Houston, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01411410" }, { "nct_id": "NCT02552394", "title": "J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "huJ591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2015-07", "completion_date": "2021-01-03", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552394" }, { "nct_id": "NCT00579527", "title": "Phase I/II Thymus Transplantation With Immunosuppression #950", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DiGeorge Anomaly", "Complete DiGeorge Anomaly", "Complete Atypical DiGeorge Anomaly", "Complete DiGeorge Syndrome", "Complete Atypical DiGeorge Syndrome" ], "interventions": [ { "name": "Cultured Thymus Tissue for Implantation (CTTI)", "type": "BIOLOGICAL" }, { "name": "Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation", "type": "OTHER" }, { "name": "Blood Draw", "type": "PROCEDURE" }, { "name": "Rabbit anti-thymocyte globulin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methylprednisolone or Prednisolone", "type": "DRUG" }, { "name": "Daclizumab", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "Sumitomo Pharma Switzerland GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 14, "start_date": "2005-12-19", "completion_date": "2017-12-31", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579527" }, { "nct_id": "NCT01986361", "title": "Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Pharyngitis", "Sore Throat" ], "interventions": [ { "name": "flurbiprofen", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reckitt Benckiser LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2013-09", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-09-28", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 1, "location_summary": "Storrs, Connecticut", "locations": [ { "city": "Storrs", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01986361" }, { "nct_id": "NCT04963296", "title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Acetaminophen/Paracetamol", "type": "DRUG" }, { "name": "Diphenhydramine hydrochloride", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 303, "start_date": "2021-10-26", "completion_date": "2028-03-13", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 14, "location_summary": "Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963296" }, { "nct_id": "NCT04106856", "title": "Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Locally Advanced Unresectable Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Losartan Potassium", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-08-08", "completion_date": "2026-02-17", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106856" }, { "nct_id": "NCT02474199", "title": "Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant Recipient", "Living Donor (of the Respective Liver Transplant Recipient)" ], "interventions": [ { "name": "darTregs", "type": "BIOLOGICAL" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Immunosuppression (IS) Withdrawal", "type": "DRUG" }, { "name": "Study Mandated Procedures", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2016-06-06", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-09-30T21:31:38.420Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02474199" } ] }